
  
    
      
        
        The_DT ongoing_JJ battle_NN between_IN hosts_NNS and_CC pathogens_NNS has_VBZ long_RB been_VBN of_IN interest_NN to_TO evolutionary_JJ
        biologists_NNS ._. Because_IN hosts_NNS and_CC pathogens_NNS act_VBP as_IN environments_NNS for_IN each_DT other_JJ ,_, their_PRP$
        intertwined_VBN struggle_NN for_IN existence_NN is_VBZ both_DT continual_JJ and_CC rapid_JJ ._. At_IN the_DT molecular_JJ level_NN ,_,
        this_DT cycle_NN of_IN environmental_JJ change_NN and_CC evolutionary_JJ response_NN means_VBZ that_IN mutations_NNS are_VBP
        continually_RB being_VBG tried_VBN out_IN by_IN natural_JJ selection_NN ._. It_PRP is_VBZ therefore_RB little_JJ wonder_VBP that_IN the_DT
        host_NN and_CC pathogen_NN genes_NNS that_WDT control_NN infection_NN and_CC immunity_NN frequently_RB show_NN high_JJ levels_NNS of_IN
        genetic_JJ diversity_NN and_CC present_VB some_DT of_IN the_DT best_JJS examples_NNS of_IN positive_JJ selection_NN (_( adaptive_JJ
        evolution_NN )_) reported_VBD to_TO date_NN (_( Yang_NNP and_CC Bielawski_NNP 2000_CD )_) ._. In_IN particular_JJ ,_, rates_NNS of_IN
        nonsynonymous_JJ substitution_NN per_IN site_NN (_( resulting_VBG in_IN an_DT amino_JJ acid_NN change_NN ;_: d_SYM
        N_NNP )_) often_RB greatly_RB exceed_VB those_DT of_IN synonymous_JJ substitution_NN per_IN site_NN
        (_( silent_JJ change_NN ;_: d_SYM
        S_NNP )_) ,_, as_IN expected_VBN if_IN most_JJS mutations_NNS are_VBP fixed_VBN because_IN they_PRP increase_VBP
        fitness_NN (_( Figure_NN 1_LS )_) ._.
        At_IN the_DT host_NN level_NN ,_, most_JJS studies_NNS of_IN the_DT selection_NN pressures_NNS acting_VBG on_IN immune_JJ system_NN genes_NNS
        have_VBP concentrated_VBN on_IN genes_NNS implicated_VBN in_IN the_DT adaptive_JJ immune_JJ response_NN against_IN microbial_NN
        pathogens_NNS ,_, particularly_RB those_DT producing_VBG antibodies_NNS (_( Sitnikova_NNP and_CC Nei_NNP 1998_CD ;_: Sumiyama_NNP et_CC al_NN ._.
        2002_CD )_) ,_, or_CC genes_NNS encoding_VBG reconnaissance_NN molecules_NNS known_VBN as_IN the_DT major_JJ histocompatibility_NN
        complex_JJ (_( MHC_NNP )_) ,_, which_WDT control_VBP the_DT action_NN of_IN T-_NNP cells_NNS (_( Hughes_NNP and_CC Nei_NNP 1988_CD ;_: Yeager_NNP and_CC Hughes_NNP
        1999_CD )_) (_( Box_NNP 1_LS )_) ._. As_IN its_PRP$ name_NN suggests_VBZ ,_, the_DT role_NN of_IN the_DT adaptive_JJ immune_JJ response_NN is_VBZ to_TO
        stimulate_VB and_CC ‘ memorise_NN’ immunity_NN to_TO specific_JJ pathogens_NNS ._. As_IN microbial_NN pathogens_NNS such_JJ as_IN
        viruses_NNS are_VBP both_DT abundant_JJ and_CC rapidly_RB evolving_VBG ,_, positive_JJ selection_NN on_IN components_NNS of_IN the_DT
        adaptive_JJ immune_JJ response_NN is_VBZ often_RB very_RB strong_JJ (_( Yeager_NNP and_CC Hughes_NNP 1999_CD )_) ._. Far_NNP less_JJR attention_NN
        has_VBZ been_VBN directed_VBN toward_IN the_DT less_RBR specific_JJ innate_JJ (_(‘ nonadaptive_JJ’ )_) immune_JJ response_NN ,_, even_RB
        though_IN this_DT response_NN requires_VBZ a_DT wide_JJ array_NN of_IN genes_NNS and_CC acts_NNS as_IN the_DT front_JJ line_NN of_IN immune_JJ
        defence_NN (_( Box_NNP 1_LS )_) ._. Would_MD we_PRP expect_VB the_DT same_JJ strength_NN of_IN positive_JJ selection_NN on_IN a_DT generalized_JJ
        pathogen_NN control_NN system_NN ?_. This_DT is_VBZ a_DT question_NN of_IN fundamental_JJ importance_NN because_IN the_DT luxury_NN of_IN
        adaptive_JJ immunity_NN is_VBZ not_RB available_JJ to_TO most_JJS organisms_NNS ,_, having_VBG probably_RB evolved_VBD along_IN with_IN
        the_DT vertebrates_NNS (_( Bartl_NNP et_CC al_NN ._. 1994_CD )_) ,_, whereas_IN the_DT more_RBR widespread_JJ innate_JJ immune_JJ system_NN is_VBZ
        often_RB depicted_VBN as_IN a_DT primitive_JJ characteristic_NN ._.
      
      
        Molecular_NNP Evolution_NNP of_IN the_DT Innate_NNP Immune_NNP System_NNP
        The_DT genes_NNS involved_VBN in_IN innate_JJ immunity_NN have_VBP recently_RB come_VB under_IN the_DT molecular_JJ
        evolutionists_NNS '_POS gaze_VBP ._. One_CD important_JJ group_NN are_VBP the_DT defensins_NNS ,_, a_DT large_JJ class_NN of_IN short_JJ
        antimicrobial_NN peptides_NNS that_WDT constitute_VBP an_DT effective_JJ immune_JJ response_NN team_NN in_IN organisms_NNS as_RB
        diverse_JJ as_IN plants_NNS and_CC primates_NNS (_( Boman_NNP 1995_CD )_) ._. Because_IN defensins_NNS are_VBP cationic_JJ (_( positively_RB
        charged_VBN )_) ,_, they_PRP are_VBP able_JJ to_TO interact_NN with_IN negatively_RB charged_VBN molecules_NNS on_IN the_DT surface_NN of_IN
        microbes_NNS and_CC permeate_NN their_PRP$ membranes_NNS ._. Sequence_NNP analyses_NNS of_IN defensins_NNS and_CC similar_JJ
        antimicrobial_NN peptides_NNS have_VBP revealed_VBN the_DT telltale_JJ signatures_NNS of_IN positive_JJ selection_NN ,_, with_IN d_SYM
        N_NNP greater_JJR than_IN d_SYM
        S_NNP in_IN many_JJ comparisons_NNS (_( Hughes_NNP 1999_CD ;_: Duda_NNP et_CC al_NN ._. 2002_CD ;_: Maxwell_NNP et_CC al_NN ._.
        2003_CD )_) ._. Other_JJ genes_NNS of_IN the_DT innate_JJ immune_JJ system_NN also_RB seem_VBP to_TO be_VB subject_JJ to_TO powerful_JJ positive_JJ
        selection_NN ._. One_CD dramatic_JJ example_NN described_VBD in_IN this_DT issue_NN of_IN 
        PLoS_NNP Biology_NNP is_VBZ the_DT APOBEC_NNP 3_CD G_NNP gene_NN of_IN primates_NNS (_( Sawyer_NNP et_CC al_NN ._. 2004_CD )_) ._. This_DT
        case_NN is_VBZ especially_RB striking_JJ because_IN rather_RB than_IN killing_VBG pathogens_NNS through_IN protein_NN or_CC
        cellular_JJ interactions_NNS ,_, like_IN most_JJS immune_JJ genes_NNS ,_, APOBEC_NNP 3_CD G_NNP works_VBZ by_IN manipulating_VBG the_DT genome_NN
        sequence_NN of_IN the_DT invading_VBG microbe_NN ._.
        The_DT genomes_NNS of_IN primates_NNS contain_VBP a_DT family_NN of_IN nine_CD APOBEC_NNP genes_NNS that_WDT encode_NN enzymes_NNS
        involved_VBN in_IN the_DT editing_NN of_IN RNA_NNP and_CC /_NN or_CC DNA_NNP through_IN the_DT deamination_NN of_IN cytosine_NN (_( C_NNP )_) ,_, so_IN that_IN
        this_DT nucleotide_NN mutates_NNS to_TO uracil_NN (_( U_NNP )_) ._. This_DT is_VBZ essential_JJ for_IN various_JJ aspects_NNS of_IN cellular_JJ
        function_NN ._. APOBEC_NNP 1_CD ,_, for_IN example_NN ,_, is_VBZ involved_VBN in_IN the_DT C_NNP →_NN U_NNP editing_NN of_IN apolipoprotein_NN B_NNP mRNA_NN
        (_( therein_RB christening_VBG the_DT family_NN )_) ,_, while_IN another_DT family_NN member_NN ,_, the_DT activation-induced_JJ
        deaminase_NN ,_, has_VBZ a_DT vital_JJ role_NN in_IN adaptive_JJ immunity_NN in_IN that_IN it_PRP assists_VBZ in_IN the_DT diversification_NN
        of_IN antibodies_NNS ._. Two_CD more_JJR enzymes_NNS ,_, APOBEC_NNP 3_CD G_NNP and_CC APOBEC_NNP 3_CD F_NN ,_, form_NN part_NN of_IN the_DT innate_JJ immune_JJ
        system_NN ;_: they_PRP function_VBP as_IN antiviral_JJ agents_NNS and_CC are_VBP being_VBG intensively_RB studied_VBN in_IN the_DT context_NN
        of_IN infection_NN with_IN the_DT human_JJ immunodeficiency_NN virus_NN (_( HIV_NNP )_) ,_, the_DT cause_NN of_IN AIDS_NNP ._. In_IN particular_JJ ,_,
        APOBEC_NNP 3_CD G_NNP targets_VBZ the_DT reverse_JJ transcription_NN step_NN of_IN the_DT HIV_NNP life_NN cycle_NN ,_, in_IN which_WDT the_DT viral_JJ
        genomic_JJ RNA_NNP is_VBZ converted_VBN into_IN proviral_NN DNA_NNP ,_, which_WDT is_VBZ then_RB integrated_VBN into_IN the_DT host_NN genome_NN
        (_( Mangeat_NNP et_CC al_NN ._. 2003_CD )_) ._. APOBEC_NNP 3_CD G-_NNP induced_VBD deamination_NN at_IN this_DT stage_NN results_NNS in_IN monotonous_JJ
        guanine-to-adenine_JJ (_( G_NNP →_NN A_DT )_) nucleotide_NN changes_NNS ,_, a_DT phenomenon_NN called_VBD G_NNP →_NN A_DT hypermutation_NN that_WDT had_VBD
        long_RB been_VBN noted_VBN by_IN HIV_NNP researchers_NNS without_IN a_DT clear_JJ understanding_NN of_IN its_PRP$ cause_NN ._. We_PRP now_RB know_VBP
        that_IN G_NNP →_NN A_DT hypermutation_NN is_VBZ part_NN of_IN the_DT innate_JJ immune_JJ response_NN to_TO retroviral_NN infections_NNS ._.
        Although_IN there_EX is_VBZ still_RB some_DT debate_NN over_IN exactly_RB how_WRB APOBEC_NNP 3_CD G_NNP leads_VBZ to_TO viral_JJ
        eradication_NN ,_, the_DT most_RBS likely_JJ scenario_NN is_VBZ that_IN G_NNP 3_CD A_DT hypermutation_NN results_NNS in_IN the_DT generation_NN
        and_CC incorporation_NN of_IN a_DT multitude_NN of_IN deleterious_JJ mutations_NNS that_WDT fatally_RB disrupt_VB viral_JJ
        functions_NNS ._. This_DT strategy_NN is_VBZ likely_JJ to_TO work_VB well_RB for_IN retroviruses_NNS like_IN HIV_NNP because_IN their_PRP$
        genomes_NNS are_VBP so_RB compact_JJ that_IN individual_JJ sequence_NN regions_NNS often_RB perform_VBP multiple_JJ functions_NNS ._.
        Under_IN these_DT cramped_JJ conditions_NNS ,_, most_JJS mutations_NNS are_VBP likely_JJ to_TO severely_RB disrupt_VB some_DT aspect_NN
        of_IN viral_JJ function_NN and_CC thereby_RB reduce_VB fitness_NN (_( Holmes_NNP 2003_CD )_) ._. Indeed_RB ,_, it_PRP has_VBZ been_VBN estimated_VBN
        that_IN the_DT deleterious_JJ mutation_NN rate_NN in_IN viruses_NNS that_WDT replicate_VB using_VBG RNA_NNP polymerases_NNS (_( either_CC
        reverse_VB transcriptase_NN in_IN the_DT case_NN of_IN retroviruses_NNS or_CC RNA-dependent_NNP RNA_NNP polymerase_NN for_IN other_JJ
        RNA_NNP viruses_NNS )_) is_VBZ on_IN the_DT order_NN of_IN one_CD error_NN per_IN replication_NN cycle_NN ,_, so_IN that_IN many_JJ of_IN the_DT viral_JJ
        progeny_NN produced_VBN by_IN replication_NN are_VBP defective_JJ (_( Elena_NNP and_CC Moya_NNP 1999_CD )_) ._. HIV_NNP is_VBZ normally_RB able_JJ
        to_TO overcome_VB this_DT burden_NN of_IN deleterious_JJ mutation_NN because_IN of_IN its_PRP$ remarkable_JJ reproductive_JJ
        power_NN ;_: each_DT day_NN ,_, on_IN the_DT order_NN of_IN 10_CD
        10_CD virions_NNS are_VBP produced_VBN in_IN a_DT single_JJ infected_JJ individual_JJ (_( Perelson_NNP et_CC al_NN ._.
        1996_CD )_) ,_, so_IN that_IN enough_RB fit_VB and_CC able_JJ recruits_VBZ will_MD make_VB it_PRP through_IN to_TO the_DT next_JJ
        generation_NN ._.
      
      
        Treating_NNP RNA_NNP Virus_NNP Infections_NNP Through_IN Lethal_NNP Mutagenesis_NNP
        The_DT high_JJ mutation_NN rates_NNS of_IN RNA_NNP viruses_NNS mean_VBP that_IN adaptively_RB useful_JJ genetic_JJ variation_NN is_VBZ
        produced_VBN frequently_RB ._. The_DT rub_NN ,_, however_RB ,_, is_VBZ that_IN fitness-enhancing_JJ mutations_NNS are_VBP a_DT small_JJ
        minority_NN ,_, and_CC the_DT preponderance_NN of_IN deleterious_JJ mutations_NNS means_VBZ that_IN RNA_NNP viruses_NNS live_VBP on_IN the_DT
        edge_NN of_IN survival_NN (_( Domingo_NNP 2000_CD )_) ._. By_IN increasing_VBG the_DT rate_NN at_IN which_WDT deleterious_JJ mutations_NNS
        appear_VBP ,_, APOBEC_NNP 3_CD G_NNP pushes_VBZ viruses_NNS over_IN this_DT edge_NN ,_, causing_VBG a_DT form_NN of_IN ‘ lethal_JJ mutagenesis_NNS’ that_IN
        results_NNS in_IN their_PRP$ destruction_NN ;_: the_DT rate_NN of_IN mutation_NN becomes_VBZ so_RB high_JJ that_IN no_DT genome_NN can_MD
        reproduce_VB itself_PRP faithfully_RB ,_, and_CC the_DT population_NN crashes_NNS ._. Intriguingly_NNP ,_, researchers_NNS
        designing_VBG new_JJ antiviral_JJ drugs_NNS have_VBP also_RB begun_VBN to_TO realise_NN that_IN forcing_VBG viruses_NNS into_IN this_DT
        sort_NN of_IN ‘ error_NN catastrophe_NN’ might_MD be_VB an_DT effective_JJ way_NN to_TO treat_VB them_PRP (_( Figure_NN 2_LS )_) ._. There_EX are_VBP a_DT
        growing_VBG number_NN of_IN studies_NNS in_IN which_WDT mutagens_NNS ,_, such_JJ as_IN ribavirin_NN and_CC 5_CD -_: fluorouracil_NN ,_, are_VBP
        applied_VBN to_TO viral_JJ infections_NNS in_IN vitro_NN and_CC in_IN vivo_NN ,_, including_VBG HIV_NNP ,_, in_IN the_DT hope_NN that_IN these_DT
        will_MD induce_VB so_RB many_JJ deleterious_JJ mutations_NNS that_IN the_DT virus_NN suffers_VBZ an_DT error_NN catastrophe_NN and_CC
        is_VBZ cleared_VBN (_( Loeb_NNP et_CC al_NN ._. 1999_CD ;_: Sierra_NNP et_CC al_NN ._. 2000_CD ;_: Crotty_NNP et_CC al_NN ._. 2001_CD ;_: Ruiz-_NNP Jarabo_NNP et_CC al_NN ._.
        2003_CD )_) ._. The_DT results_NNS produced_VBN to_TO date_NN are_VBP highly_RB encouraging_VBG ,_, particularly_RB when_WRB these_DT
        error-inducing_JJ drugs_NNS are_VBP combined_VBN with_IN more_RBR conventional_JJ treatment_NN strategies_NNS that_WDT aim_NN to_TO
        reduce_VB the_DT rate_NN of_IN viral_JJ replication_NN (_( Pariente_NNP et_CC al_NN ._. 2001_CD )_) ._. The_DT discovery_NN that_IN a_DT natural_JJ
        antiviral_JJ agent_NN ,_, APOBEC_NNP 3_CD G_NNP ,_, probably_RB works_VBZ in_IN much_RB the_DT same_JJ way_NN should_MD provide_VB even_RB more_JJR
        encouragement_NN ._.
        Sadly_RB ,_, however_RB ,_, the_DT pathogens_NNS have_VBP fought_VBN back_RB ._. The_DT anti-_NN HIV_NNP properties_NNS of_IN APOBEC_NNP 3_CD G_NNP were_VBD
        discovered_VBN because_IN most_JJS viral_JJ strains_NNS escape_VB its_PRP$ neutralising_VBG properties_NNS ._. Lentiviruses_NNP like_IN
        HIV_NNP possess_VBP a_DT gene_NN that_IN encodes_NNS an_DT protein_NN called_VBD Vif_NNP (_(‘ viral_JJ infectivity_NN factor_NN’ )_) that_IN
        counters_NNS APOBEC_NNP 3_CD G_NNP (_( Sheehy_NNP et_CC al_NN ._. 2002_CD )_) ._. Hence_RB ,_, it_PRP is_VBZ probably_RB only_RB in_IN naturally_RB occurring_VBG
        Vif-defective_NNP mutants_NNS that_IN APOBEC_NNP 3_CD G_NNP is_VBZ effective_JJ against_IN HIV_NNP ._. Furthermore_RB ,_, because_IN positive_JJ
        selection_NN on_IN APOBEC_NNP 3_CD G_NNP has_VBZ operated_VBN for_IN at_IN least_JJS 30_CD million_CD years_NNS and_CC lentiviruses_NNS in_IN
        general_JJ ,_, and_CC HIV_NNP in_IN particular_JJ ,_, are_VBP likely_JJ to_TO be_VB more_RBR recently_RB evolved_VBD than_IN this_DT ,_, it_PRP is_VBZ
        clear_JJ that_IN a_DT broad_JJ range_NN of_IN retroviral_NN pathogens_NNS have_VBP been_VBN responsible_JJ for_IN the_DT adaptive_JJ
        evolution_NN of_IN this_DT particular_JJ immune_JJ gene_NN (_( Sawyer_NNP et_CC al_NN ._. 2004_CD )_) ._. Given_VBN the_DT frequency_NN with_IN
        which_WDT the_DT remnants_NNS of_IN past_JJ retroviral_NN infections_NNS are_VBP found_VBN in_IN the_DT mammalian_JJ genome_NN (_( Smit_NNP
        1999_CD )_) ,_, in_IN the_DT form_NN of_IN usually_RB defunct_JJ endogenous_JJ retroviruses_NNS (_( Box_NNP 1_LS )_) ,_, it_PRP is_VBZ likely_JJ that_IN
        our_PRP$ genomes_NNS are_VBP continually_RB bombarded_VBN with_IN retroviruses_NNS like_IN HIV_NNP but_CC that_IN the_DT majority_NN are_VBP
        cleared_VBN by_IN innate_JJ immune_JJ mechanisms_NNS like_IN APOBEC_NNP 3_CD G_NNP ._. It_PRP is_VBZ possible_JJ that_IN the_DT retroviruses_NNS
        that_WDT successfully_RB infect_NN us_PRP are_VBP those_DT ,_, like_IN HIV_NNP ,_, that_WDT have_VBP managed_VBN to_TO evolve_VB strategies_NNS to_TO
        avoid_VB the_DT destructive_JJ capacities_NNS of_IN APOBEC_NNP 3_CD G_NNP ._.
        The_DT intense_JJ selective_JJ pressure_NN on_IN the_DT defensins_NNS and_CC APOBEC_NNP 3_CD G_NNP illustrates_VBZ that_IN although_IN
        the_DT innate_JJ immune_JJ response_NN is_VBZ generalist_NN in_IN its_PRP$ action_NN ,_, it_PRP is_VBZ as_RB highly_RB and_CC intricately_RB
        evolved_VBD as_IN its_PRP$ better-studied_JJ ally_NN ,_, the_DT adaptive_JJ immune_JJ system_NN ._. Rather_RB than_IN being_VBG an_DT
        evolutionary_JJ remnant_NN ,_, it_PRP is_VBZ a_DT dynamic_JJ and_CC continually_RB adapting_VBG system_NN ._. Less_RBR clear_JJ is_VBZ
        whether_IN other_JJ host_NN proteins_NNS act_VBP in_IN the_DT same_JJ manner_NN as_IN APOBEC_NNP 3_CD G_NNP ._. In_IN particular_JJ ,_, the_DT most_RBS
        common_JJ and_CC destructive_JJ pathogens_NNS faced_VBN by_IN humans_NNS and_CC other_JJ mammals_NNS are_VBP RNA_NNP viruses_NNS ,_, such_JJ as_IN
        influenza_NN A_DT ,_, yellow_JJ fever_NN ,_, and_CC hepatitis_NNP C_NNP ._. In_IN most_JJS cases_NNS ,_, our_PRP$ ability_NN to_TO survive_VB these_DT
        viral_JJ infections_NNS is_VBZ simply_RB a_DT combination_NN of_IN good_JJ luck_NN and_CC good_NN breeding_NN ;_: with_IN the_DT right_JJ
        combination_NN of_IN MHC_NNP alleles_NNS ,_, itself_PRP a_DT function_NN of_IN population_NN history_NN and_CC what_WP we_PRP by_IN chance_NN
        inherit_VBP from_IN our_PRP$ parents_NNS ,_, some_DT individuals_NNS may_MD be_VB more_RBR able_JJ to_TO fight_VB off_RP viral_JJ infections_NNS
        than_IN others_NNS ._. The_DT ubiquity_NN of_IN RNA_NNP viruses_NNS hints_NNS that_IN our_PRP$ genomes_NNS might_MD also_RB contain_VB an_DT
        innate_JJ ,_, yet_RB highly_RB adapted_VBN ,_, defence_NN system_NN that_IN targets_NNS this_DT abundant_JJ class_NN of_IN pathogens_NNS by_IN
        manipulating_VBG their_PRP$ mutation_NN rate_NN ._. Although_IN utilizing_VBG lethal_JJ mutagenesis_NNS might_MD one_CD day_NN be_VBP an_DT
        important_JJ way_NN to_TO design_VB new_JJ drugs_NNS against_IN a_DT variety_NN of_IN viral_JJ pathogens_NNS ,_, it_PRP would_MD come_VB as_IN no_DT
        surprise_NN if_IN nature_NN got_VBD there_RB first_JJ ._.
      
    
  
